{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:36:29Z","timestamp":1790516189143,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"am","delay-in-days":391,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.gofs.2018.12.006","type":"journal-article","created":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T07:40:06Z","timestamp":1548574806000},"page":"250-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Surveillance apr\u00e8s traitement initial d\u2019une tumeur \u00e9pith\u00e9liale de l\u2019ovaire, place du traitement hormonal de la m\u00e9nopause et de la contraception. Article r\u00e9dig\u00e9 sur la base de la recommandation nationale de bonnes pratiques cliniques en canc\u00e9rologie intitul\u00e9e \u00ab\u00a0Conduites \u00e0 tenir initiales devant des patientes atteintes d\u2019un cancer \u00e9pith\u00e9lial de l\u2019ovaire\u00a0\u00bb \u00e9labor\u00e9e par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY sous l\u2019\u00e9gide du CNGOF et labellis\u00e9e par l\u2019INCa"],"prefix":"10.1016","volume":"47","author":[{"given":"C.","family":"S\u00e9n\u00e9chal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Akladios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bendifallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ouldamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lecuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rousset-Jablonski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gofs.2018.12.006_bib0330","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1056\/NEJM199311183292108","article-title":"Cancer of the ovary","volume":"329","author":"Cannistra","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gofs.2018.12.006_bib0335","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gofs.2018.12.006_bib0340","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gofs.2018.12.006_bib0345","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.critrevonc.2008.12.008","article-title":"Surveillance of patients after initial treatment of ovarian cancer","volume":"71","author":"Gadducci","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.gofs.2018.12.006_bib0350","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin and cis-platin in women with ovarian cancer: the ICON3\u00a0randomised trial","volume":"360","author":"International Collaborative Ovarian Neoplasm (ICON) Group","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.gofs.2018.12.006_bib0355","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/annonc\/mdn601","article-title":"Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer(EOC) with a low-level increase of serum CA-125\u00a0levels","volume":"20","author":"Prat","year":"2009","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2018.12.006_bib0360","first-page":"182","article-title":"Has serum CA 125\u00a0assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy?","volume":"37","author":"Gadducci","year":"2016","journal-title":"Eur J Gynaecol Oncol"},{"issue":"9","key":"10.1016\/j.gofs.2018.12.006_bib0365","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/IGC.0000000000000007","article-title":"Ovarian Cancer: sites of recurrence","volume":"23","author":"Amate","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.gofs.2018.12.006_bib0370","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2012.05.026","article-title":"Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy","volume":"127","author":"Esselen","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2018.12.006_bib0375","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ygyno.2013.04.055","article-title":"Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers","volume":"130","author":"Dao","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2018.12.006_bib0380","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ygyno.2006.02.005","article-title":"Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125\u00a0levels","volume":"103","author":"Menczer","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"3A","key":"10.1016\/j.gofs.2018.12.006_bib0385","first-page":"1551","article-title":"Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients","volume":"25","author":"Fehm","year":"2005","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.gofs.2018.12.006_bib0390","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ygyno.2013.09.017","article-title":"Evaluation of the cost of CA-125\u00a0measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer","volume":"131","author":"Armstrong","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.gofs.2018.12.006_bib0395","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/sj.bjc.6605963","article-title":"The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review","volume":"103","author":"Rettenmaier","year":"2010","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.gofs.2018.12.006_bib0400","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/IGC.0000000000000877","article-title":"Ovarian cancer follow-up: a preliminary comparison of 2\u00a0approaches","volume":"27","author":"Lanceley","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.gofs.2018.12.006_bib0405","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejrad.2008.02.019","article-title":"CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis","volume":"71","author":"Gu","year":"2009","journal-title":"Eur J Radiol"},{"issue":"1","key":"10.1016\/j.gofs.2018.12.006_bib0410","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13048-016-0266-3","article-title":"The significance of the change pattern of serum CA125\u00a0level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer","volume":"9","author":"Yang","year":"2016","journal-title":"J Ovarian Res"},{"issue":"9747","key":"10.1016\/j.gofs.2018.12.006_bib0415","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed\u00a0ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.gofs.2018.12.006_bib0420","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.2006.09.4540","article-title":"An early signal of CA-125\u00a0progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy","volume":"25","author":"Liu","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2018.12.006_bib0425","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/annonc\/mdn601","article-title":"Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125\u00a0levels","volume":"20","author":"Prat","year":"2009","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.gofs.2018.12.006_bib0430","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1097\/IGC.0b013e3182691254","article-title":"Prognostic significance of rising serum CA-125\u00a0levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response","volume":"22","author":"Levy","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.gofs.2018.12.006_bib0435","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12032-017-1026-y","article-title":"Ovarian cancer recurrence and early detection: may HE4\u00a0play a key role in this open challenge? A systematic review of literature","volume":"34","author":"Capriglione","year":"2017","journal-title":"Med Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2018.12.006_bib0440","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2008.04.041","article-title":"Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence","volume":"110","author":"Havrilesky","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2018.12.006_bib0445","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","article-title":"HE4: a new potential early biomarker for the recurrence of ovarian cancer","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumour Biol"},{"issue":"1","key":"10.1016\/j.gofs.2018.12.006_bib0450","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2011.11.050","article-title":"Evaluation of ovarian cancer remission markers HE4, MMP7\u00a0and Mesothelin by comparison to the established marker CA125","volume":"125","author":"Schummer","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.gofs.2018.12.006_bib0455","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s13277-012-0381-8","article-title":"Role of HE4, CA72.4, and CA125\u00a0in monitoring ovarian cancer","volume":"33","author":"Granato","year":"2012","journal-title":"Tumour Biol"},{"issue":"6","key":"10.1016\/j.gofs.2018.12.006_bib0460","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s13277-012-0471-7","article-title":"Does HE4\u00a0have a role as biomarker in the recurrence of ovarian cancer?","volume":"33","author":"Plotti","year":"2012","journal-title":"Tumour Biol"},{"issue":"5","key":"10.1016\/j.gofs.2018.12.006_bib0465","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.3892\/or.2013.2682","article-title":"Serum HE4\u00a0levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer","volume":"30","author":"Manganaro","year":"2013","journal-title":"Oncol Rep"},{"issue":"9","key":"10.1016\/j.gofs.2018.12.006_bib0470","first-page":"4483","article-title":"Does human epididymis protein 4 (HE4) have a role in prediction of recurrent epithelial ovarian cancer","volume":"17","author":"Innao","year":"2016","journal-title":"Asian Pac J cancer Prev"},{"issue":"4","key":"10.1016\/j.gofs.2018.12.006_bib0475","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/14737159.2018.1457436","article-title":"Prognostic value of serum and tissue HE4\u00a0expression in ovarian cancer: a systematic review with meta-analysis of 90\u00a0studies","volume":"18","author":"Cao","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"10.1016\/j.gofs.2018.12.006_bib0480","first-page":"239","article-title":"The diagnostic value of magnetic resonance imaging for the detection of tumor recurrence in patients with carcinoma of the ovaries","volume":"178","author":"Kainz","year":"1994","journal-title":"J Am Coll Surg"},{"issue":"10","key":"10.1016\/j.gofs.2018.12.006_bib0485","first-page":"746","article-title":"The value of FDG PET\/CT, ultrasound and CT in diagnosing recurrent ovarian carcinoma","volume":"77","author":"Grabiec","year":"2006","journal-title":"Ginekol Pol"},{"issue":"10","key":"10.1016\/j.gofs.2018.12.006_bib0490","first-page":"1296","article-title":"Transvaginal color doppler ultrasonography and CA125\u00a0detection in surveillance of ovarianmalignant tumors after operation","volume":"25","author":"Zeng","year":"2006","journal-title":"Ai Zheng"},{"issue":"3","key":"10.1016\/j.gofs.2018.12.006_bib0495","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1148\/radiol.2015142467","article-title":"Advanced high-grade serous ovarian cancer: frequency and timing of thoracic metastases and the implications for chest imaging follow-up","volume":"277","author":"Shinagare","year":"2015","journal-title":"Radiology"},{"issue":"5","key":"10.1016\/j.gofs.2018.12.006_bib0500","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00330-002-1712-8","article-title":"Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer","volume":"13","author":"Ricke","year":"2003","journal-title":"Eur Radiol"},{"issue":"9","key":"10.1016\/j.gofs.2018.12.006_bib0505","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s00259-007-0366-9","article-title":"Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovariancarcinoma","volume":"34","author":"Garc\u00eda-Velloso","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.gofs.2018.12.006_bib0510","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ygyno.2004.12.007","article-title":"FDG-PET for management of cervical and ovarian cancer","volume":"97","author":"Havrilesky","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2018.12.006_bib0515","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ygyno.2006.03.004","article-title":"The impact of PET\/CT in the management of recurrent ovarian cancer","volume":"103","author":"Simcock","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.006_bib0520","first-page":"CD006119","article-title":"Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment","volume":"9","author":"Clarke","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.gofs.2018.12.006_bib0525","first-page":"1015","article-title":"Ultrasonographic-guided pervaginal cul-de-sac cytology in the follow-up of ovarian carcinoma","volume":"27","author":"Vuento","year":"2007","journal-title":"Anticancer Res"},{"issue":"11","key":"10.1016\/j.gofs.2018.12.006_bib0530","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/sj.bjc.6605963","article-title":"The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review","volume":"103","author":"Rettenmaier","year":"2010","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.gofs.2018.12.006_bib0535","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2005.11.046","article-title":"A study to evaluate the use of CA125\u00a0in ovarian cancer follow-up: a change in practice led by patient preference","volume":"101","author":"Palmer","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.gofs.2018.12.006_bib0540","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.3802\/jgo.2016.27.e46","article-title":"Comparison of survival outcomes after recurrence detected by cancer antigen 125\u00a0elevation versus imaging study in epithelial ovarian cancer","volume":"27","author":"Paik","year":"2016","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.006_bib0545","first-page":"CD008765","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","volume":"2","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.gofs.2018.12.006_bib0550","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl","key":"10.1016\/j.gofs.2018.12.006_bib0555","article-title":"Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20","volume":"35","author":"du Bois","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gofs.2018.12.006_bib0560","unstructured":"Institut National du Cancer. Th\u00e9saurus \u2013 Femmes porteuses d\u2019une mutation de BRCA1\u00a0ou BRCA2\/D\u00e9tection pr\u00e9coce du cancer du sein et des annexes et strat\u00e9gies de r\u00e9duction du risque, Collection recommandations et r\u00e9f\u00e9rentiels, INCa, avril 2017."},{"key":"10.1016\/j.gofs.2018.12.006_bib0565","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/modpathol.3800510","article-title":"Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124\u00a0cases","volume":"19","author":"Vang","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.gofs.2018.12.006_bib0570","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.gofs.2018.12.006_bib0575","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ygyno.2012.10.013","article-title":"Quantification of ER\/PR expression in ovarian low-grade serous carcinoma","volume":"128","author":"Escobar","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2018.12.006_bib0580","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2018.12.006_bib0585","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ygyno.2015.07.109","article-title":"Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis","volume":"139","author":"Li","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.gofs.2018.12.006_bib0590","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3109\/13697137.2013.806472","article-title":"The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China","volume":"16","author":"Wen","year":"2013","journal-title":"Climacteric"},{"key":"10.1016\/j.gofs.2018.12.006_bib0595","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.2015.60.9719","article-title":"Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial","volume":"33","author":"Eeles","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gofs.2018.12.006_bib0600","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1002\/ijc.22218","article-title":"Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival","volume":"119","author":"Mascarenhas","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.gofs.2018.12.006_bib0605","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/AOG.0000000000001396","article-title":"Hormone use after nonserous epithelial ovarian cancer: overall and disease-free survival","volume":"127","author":"Power","year":"2016","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.gofs.2018.12.006_bib0610","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(14)61687-1","article-title":"Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52\u00a0epidemiological studies","volume":"385","author":"Beral","year":"2015","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"10.1016\/j.gofs.2018.12.006_bib0615","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/AOG.0000000000001387","article-title":"Association between menopausal estrogen-only therapy and ovarian carcinoma risk","volume":"127","author":"Lee","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.gofs.2018.12.006_bib0620","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/GME.0000000000000550","article-title":"Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis","volume":"23","author":"Shi","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.gofs.2018.12.006_bib0625","series-title":"Traitements hormonaux substitutifs de la m\u00e9nopause\u00a0\u2013\u00a0Orientations g\u00e9n\u00e9rales\u00a0\u2013\u00a0Conclusions et Recommandations\u00a0\u00bb ANAESAFSSAPS","year":"2004"},{"key":"10.1016\/j.gofs.2018.12.006_bib0630","series-title":"Communiqu\u00e9e de presse \u00ab\u00a0Traitements hormonaux de la menopause\u00a0\u00bb","author":"HAS","year":"2014"},{"issue":"9609","key":"10.1016\/j.gofs.2018.12.006_bib0635","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45\u00a0epidemiological studies including 23,257\u00a0women with ovarian cancer and 87,303\u00a0controls","volume":"371","author":"Beral","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.gofs.2018.12.006_bib0640","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/sj.bjc.6601715","article-title":"Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study","volume":"90","author":"Kumle","year":"2004","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.gofs.2018.12.006_bib0645","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/0284186X.2016.1175660","article-title":"Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube","volume":"55","author":"Soini","year":"2016","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.gofs.2018.12.006_bib0325","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.contraception.2010.02.013","article-title":"Intrauterine device use among women with ovarian cancer: a systematic review","volume":"82","author":"Zapata","year":"2010","journal-title":"Contraception"}],"container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718918303611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718918303611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:37:09Z","timestamp":1762853829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468718918303611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S2468718918303611"],"URL":"https:\/\/doi.org\/10.1016\/j.gofs.2018.12.006","relation":{},"ISSN":["2468-7189"],"issn-type":[{"value":"2468-7189","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surveillance apr\u00e8s traitement initial d\u2019une tumeur \u00e9pith\u00e9liale de l\u2019ovaire, place du traitement hormonal de la m\u00e9nopause et de la contraception. Article r\u00e9dig\u00e9 sur la base de la recommandation nationale de bonnes pratiques cliniques en canc\u00e9rologie intitul\u00e9e \u00ab\u00a0Conduites \u00e0 tenir initiales devant des patientes atteintes d\u2019un cancer \u00e9pith\u00e9lial de l\u2019ovaire\u00a0\u00bb \u00e9labor\u00e9e par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY sous l\u2019\u00e9gide du CNGOF et labellis\u00e9e par l\u2019INCa","name":"articletitle","label":"Article Title"},{"value":"Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gofs.2018.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}